Replies to post #242790 on Biotech Values

[dewophile]

GSK/RSV
This one could have gone either way after the halt on the Maternal RSV study. It does bolster the odds of success for other companies of course
PS: NVAX had an RSV candidate that failed although I think it was a narrow miss

[DewDiligence]

PFE—Phase-3 data_for adult RSV vaccine look_good_enough_for_approval:

https://www.businesswire.com/news/home/20220825005052/en/

A separate phase-3 trial in pregnant mothers (to protect newborns) is expected to read out in 2023.

Note: PFE’s RSVpreF is an RSV vaccine—not an RSV treatment like ENTA’s EDP-938 and EDP-323. PFE’s main competitor in RSV vaccines is GSK (#msg-169113410).